Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -608.92M | -574.92M | -579.57M | -532.67M | -549.32M |
| Total Depreciation and Amortization | 34.01M | 35.01M | 35.76M | 35.91M | 36.16M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 95.75M | 96.75M | 98.92M | 100.33M | 109.87M |
| Change in Net Operating Assets | -17.37M | -22.37M | -122.00K | -24.15M | 14.02M |
| Cash from Operations | -496.53M | -465.53M | -445.01M | -420.58M | -389.27M |
| Capital Expenditure | -5.68M | -5.68M | -4.90M | -5.24M | -4.79M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.79M | 241.79M | 415.76M | 23.42M | 12.35M |
| Cash from Investing | 67.11M | 236.11M | 410.86M | 18.18M | 7.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 85.84M | 85.84M | 86.60M | 90.77M | 392.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 392.00M | 392.00M | 0.00 | 7.00M | 7.06M |
| Cash from Financing | 477.84M | 478.00M | 86.75M | 97.93M | 399.22M |
| Foreign Exchange rate Adjustments | 1.55M | 3.55M | 2.26M | 3.24M | -321.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.98M | 251.98M | 54.71M | -301.40M | 17.03M |